Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for IBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -281.14M
March 31, 2026 -294.39M
December 31, 2025 -304.94M
September 30, 2025 -319.70M
June 30, 2025 -349.56M
March 31, 2025 -370.16M
December 31, 2024 -391.24M
September 30, 2024 -421.36M
June 30, 2024 -410.00M
March 31, 2024 -389.43M
December 31, 2023 -366.76M
September 30, 2023 -342.21M
June 30, 2023 -335.41M
March 31, 2023 -346.89M
December 31, 2022 -337.51M
September 30, 2022 -318.42M
June 30, 2022 -310.54M
March 31, 2022 -288.88M
December 31, 2021 -274.42M
September 30, 2021 -225.84M
June 30, 2021 -171.40M
March 31, 2021 -118.33M
Date Value
December 31, 2020 -70.45M
September 30, 2020 -62.28M
June 30, 2020 -60.57M
March 31, 2020 -60.88M
December 31, 2019 -61.36M
September 30, 2019 -60.51M
June 30, 2019 -61.51M
March 31, 2019 -60.95M
December 31, 2018 -63.38M
September 30, 2018 -62.99M
June 30, 2018 -55.55M
March 31, 2018 -54.23M
December 31, 2017 -48.78M
September 30, 2017 -45.89M
June 30, 2017 -46.44M
March 31, 2017 -39.79M
December 31, 2016 -38.59M
September 30, 2016 -38.92M
June 30, 2016 -32.42M
March 31, 2016 -32.26M
December 31, 2015 -25.30M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Moderna, Inc. -1.073B
Sarepta Therapeutics, Inc. 93.95M
Arrowhead Pharmaceuticals, Inc. -59.06M
Oncolytics Biotech, Inc. -26.52M
Sangamo Therapeutics, Inc. -90.34M